Utilex Receives Approval for Additional Phase 1/2a Clinical Trial of Anti-Cancer Autoimmune Cell Therapy App B& T Cell
[Asia Economy Reporter Minwoo Lee] Eutilex announced on the 12th that it has received approval from the Ministry of Food and Drug Safety for an additional clinical trial plan for the Phase 1/2a clinical trial of the anti-cancer autologous immune cell therapy 'AppBNTCell.' Accordingly, the efficacy and safety of AppBNTCell will be evaluated in patients with Epstein-Barr virus (EBV) positive lymphoma and solid tumors at five institutions, including Samsung Seoul Hospital and the National Cancer Center.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Australia Orders Chinese Investors Out of Rare Earth Firms... China Immediately Pushes Back
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "AppBNTCell is an autologous cell therapy in which blood is collected from patients with EBV-positive lymphoma and solid tumors, and cancer antigen-specific T lymphocytes are mass-cultured in the laboratory and then re-administered to the patient," adding, "It is expected to minimize treatment side effects, reduce and control tumor size, extend progression-free survival, and prolong overall survival."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
